BOCH
ENGNW icon

Blue Owl Capital Holdings’s enGene Therapeutics Warrants ENGNW Stock Holding History

Blue Owl Capital Holdings’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Hold
511,177
– – 0.02% 46
2026
Q1 		$1.29M Buy
511,177
+475,077
+1,316% +$1.41M 0.35% 35
2025
Q4 		$103K Hold
36,100
– – 0.03% 51
2025
Q3 		$25.6K Hold
36,100
– – 0.01% 55
2025
Q2 		$29.6K Hold
36,100
– – 0.01% 54
2025
Q1 		$21.7K Hold
36,100
– – 0.01% 53
2024
Q4 		$30.4K Sell
36,100
-475,077
-93% -$701K 0.01% 55
2024
Q3 		$728K Buy
511,177
+460,000
+899% +$543K 0.14% 48
2024
Q2 		$608K Sell
51,177
-460,000
-90% -$1.47M 0.17% 36
2024
Q1 		$2.66M Buy
511,177
+36,100
+8% +$110K 0.53% 31
2023
Q4 		$404K Buy
+475,077
New +$365K 0.1% 38

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Blue Owl Capital Holdings's ENGNW Position: Q2 2026 in Review

Blue Owl Capital Holdings held its enGene Therapeutics Warrants (ENGNW) position steady in Q2 2026 at 511,177 shares worth $148K. The position accounts for 0.02% of the portfolio, ranked #46.

Blue Owl Capital Holdings first reported a position in ENGNW in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.66M in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

  • Blue Owl Capital Holdings held 511,177 shares of enGene Therapeutics Warrants worth $148K as of Q2 2026.
  • Blue Owl Capital Holdings left its enGene Therapeutics Warrants share count unchanged in Q2 2026.
  • enGene Therapeutics Warrants made up 0.02% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #46 holding.
  • Blue Owl Capital Holdings first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 11 quarters since.
  • Blue Owl Capital Holdings's enGene Therapeutics Warrants position peaked at $2.66M in Q1 2024.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.